ALS
The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners.
PrecisionLife, Metrodora Institute Partner on Chronic Disease Dx, Treatments
The firms plan to develop new diagnostics that identify patient risk of chronic diseases and study existing medicines that could be repurposed as treatments.
Expert Panel Publishes Guidelines for Genetic Testing, Counseling in ALS
Recommendations call for testing all people with ALS and seek to harmonize laboratory testing and reporting practices.
Amarantus Reacquires Neurology Diagnostic Assets from Avant
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.